Agreements signed with three new partners, bringing the total number of new AAV customers in 2022 to four, ahead of original target
Oxford, UK – 14 December 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”), a high-performing full-scope AAV manufacturing and innovation business, has signed agreements with three new, undisclosed, U.S. based biotechnology companies. This is in addition to the new AAV customer announced in September 2022. Oxford Biomedica Solutions has now secured four new AAV customers, ahead of the previously stated target of two by the end of the calendar year.
Under these additional agreements, Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ pre-clinical gene therapy programmes, which cover development programmes in indications including CNS, autoimmune disease, oncology, muscular disorder, and rare metabolic disease. Oxford Biomedica Solutions’ end-to-end capabilities range from construct design to process development to IND support and GMP manufacturing, including a proven platform that has demonstrated high quality titres of E15 vg/L and achieved over 90% fully intact vector.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: “Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations. AAV is a significant, high growth market, and the cadence of new business wins further reinforces our confidence in the potential of our AAV platform, which has already demonstrated high titre product quality and a full breadth of capabilities. We enter 2023 with great confidence and look forward to continuing to build our position as a world-class, innovation-led CDMO delivering life-changing and life-altering therapies to patients.”
-Ends-
Enquiries:
Oxford Biomedica plc:
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 783 000
Taylor Boyd, VP, Head of IR T: +1 919 539 1234 E: ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR T: +44 ( 7394 562 425 E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 E: oxfordbiomedica@con silium comms.com
Mary Jane Elliott Matthew Cole Angela Gray
About Oxford Biomedica
Oxford Biomedica (LSE: is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno associated virus ( and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre clinical to comme rcial stage across a range of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufactu ring and innovation business, based near Boston, US. Further information is available at www.oxb.com and www.oxbsolutions.com.